ANI PHARMACEUTICALS, INC. (NASDAQ:ANIP) Files An 8-K Other EventsItem 8.01.
On June 12, 2017, ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) filed a shelf registration statement on Form S-3 (the “Registration Statement”) with the Securities and Exchange Commission which, when declared effective by the SEC, will allow ANI to offer and sell, from time to time, up to an aggregate of $350 million of securities. The Registration Statement is being filed to replace ANI’s current shelf registration on Form S-3, which was set to expire on June 12, 2017. ANI believes it is prudent to have an effective shelf registration statement on file with the SEC to preserve flexibility to raise capital, if needed. ANI has no current plans to sell any securities under the Registration Statement.
About ANI PHARMACEUTICALS, INC. (NASDAQ:ANIP)
ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company’s focused areas of product development include anti-cancer (oncolytics), hormones and steroids, and complex formulations. Its generic products include Esterified Estrogen with Methyltestosterone, Etodolac, Flecainide, Fluvoxamine, Hydrocortisone Enema, Methazolamide, Metoclopramide Syrup, Nimodipine, Opium Tincture, Oxycodone Oral Solution, Propafenone and Vancomycin. Its branded products include Cortenema, Lithobid, Reglan and Vancocin. It has over two pharmaceutical manufacturing facilities located in Baudette, Minnesota that are capable of producing oral solid dose products, as well as liquids and topicals, controlled substances, and potent products. Its two facilities have a combined manufacturing, packaging and laboratory capacity totaling approximately 173,000 square feet.
